Keywords
Key points
- •History, physical examination, including vital signs and saturation of peripheral oxygen, and chest radiographs results provide the essential information to clinically diagnose community-acquired pneumonia.
- •Careful severity assessment is a crucial step in the emergency department management of community-acquired pneumonia and should include screening for occult sepsis with a serum lactate, followed by early antibiotics and fluid resuscitation when indicated.
- •Risk stratification tools such as the PSI and CURB-65 should be used routinely to determine the most appropriate disposition.
- •Emergency department providers need to be aware of risk factors for multidrug-resistant pneumonia, limiting broad spectrum antibiotics to patients satisfying guideline-recommended criteria.
Introduction
Rui P, Kang K. National hospital ambulatory medical care survey: 2015 emergency department summary tables. Available at: http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2015_ed_web_tables.pdf.
Microbiology
Patient Population | Pathogens |
---|---|
Otherwise healthy adult, bacterial | Streptococcus pneumoniae Mycoplasma pneumoniae Staphylococcus aureus Legionella pneumophila Haemophilus influenzae Chlamydophila pneumoniae Moraxella catarrhalis |
Otherwise healthy adult, viral | Human rhinovirus Influenza Human metapneumovirus Parainfluenza virus Respiratory syncytial virus Coronavirus Adenovirus |
Adults with health care exposure | Pseudomonas aeruginosa S aureus Klebsiella pneumoniae Escherichia coli |
| E coli Listeria monocytogenes Group B streptococci Chlamydia trachomatis Streptococcus pneumoniae C trachomatis Streptococcus pneumoniae M pneumoniae Respiratory syncytial virus Influenza Parainfluenza Adenovirus Rhinovirus C pneumoniae M pneumoniae Streptococcus pneumoniae M catarrhalis H influenzae S aureus |
Unusual and opportunistic infectious etiologies | Pneumocystic jiroveci Histoplasma capsulatum Blastomyces Coccidioidomycosis Aspergillus Candida albicans Mucorales Cryptococcus neoformans Coxiella burnetii Mycobacterium tuberculosis |
Microbiology: drug-resistant pathogens
Drug-Resistant Pathogen | Risk Factors |
---|---|
Drug-resistant streptococcus | Age >65 Beta-lactam or macrolide therapy within 3 mo Immunosuppression Alcoholism Daycare centers Medical comorbidities |
Enteric gram negative | Residence in a nursing home Recent hospitalization Recent antibiotics Cardiopulmonary disease Smoking Underlying malignancy |
MRSA | Age >74 y Dialysis Prior MRSA infection Prior hospitalization Recent nursing home stay Medical comorbidities |
Pseudomonas | Chronic obstructive pulmonary disease Immunosuppression Recent steroid exposure Hemiplegia Recent antibiotics against gram positive organisms Recent hospitalization |
Pathophysiology
Epidemiology
Differential diagnosis
Chest Radiograph Findings | Causes |
---|---|
Abnormal chest radiograph, infectious | Refer to micro table |
Abnormal chest radiograph, noninfectious | Cardiogenic pulmonary edema Bronchiectasis Pulmonary infarction Arteriovenous malformation Interstitial lung disease Cryptogenic organizing pneumonia Acute eosinophilic pneumonia Pneumonitis Vasculitis Cocaine-induced lung injury Pulmonary contusion Drug reaction High altitude pulmonary edema Lung cancer |
Normal chest radiograph | Bronchitis Asthma Gastroesophageal reflux disease Upper respiratory tract infection Medication side-effect |
Diagnosis: History and Physical Examination

Diagnosis: Imaging

Diagnosis: Additional Testing
- Lam S.W.
- Bauer S.R.
- Fowler R.
- et al.

Severity assessment and clinical decision rules
- •Respiratory rate of greater than 30 breaths per minute;
- •Pao2/Fio2 of less than 250;
- •Multilobar infiltrates;
- •Confusion;
- •Uremia;
- •Leukopenia;
- •Thrombocytopenia;
- •Hypothermia; and
- •Hypotension.
Clinical Decision Rule | Factors | Points | Score and Stratification | |||
---|---|---|---|---|---|---|
Pneumonia Severity Index (PSI) | Male Age >50 Nursing home resident Neoplastic disease Congestive heart failure Cerebrovascular disease Renal disease Liver disease Altered mental status HR ≥125 beats/min RR ≥30 breaths/min Systolic BP <90 mm Hg Temperature <35°C or ≥40°C Arterial pH <7.35 BUN ≥30 mg/dL Sodium <130 mmol/L Glucose ≥250 mg/dL Hematocrit <30% Partial pressure arterial O2 <60 mm Hg or O2 sat <90% Pleural effusion | Age Age + 10 30 30 10 10 10 20 20 10 20 20 15 30 20 20 10 10 10 10 | Point total If all are absent ≤70 low risk 71–90 low risk 91–130 moderate >130 high risk | Risk class I II III IV V | Mortality Class I: 0.1%–0.4% Class II: 0.6%–0.7% Class III: 0.9%–2.8% Class IV: 8.2%–12.5% Class V: 27.1%–31.1% | Suggested Disposition I, II: outpatient III: observation IV, V: hospitalize |
British Thoracic Society (BTS) modified Or CURB-65 | Confusion/orientation BUN >20 mg/dL (7 mmol/L) RR ≥30 breaths/min Low BP: <90 SBP, ≤60 DBP Age ≥65 y | 1 1 1 1 1 | Score total 0–5 | Mortality (30-d) 0 factors: 0.7% 1 factors: 2.1% 2 factors: 9.2% 3 factors: 14.5% 4 factors: 40% 5 factors: 57% | Suggested Disposition 0–1: treat as outpatients 2: admit to floor ≥3: ICU |
Treatment
Patient Characteristics | Regimen |
---|---|
Outpatient: previously healthy | Macrolide Doxycycline |
Outpatient: with comorbidities (heart, lung renal disease, diabetes, alcoholism) or recent use of antibiotics concerning for drug-resistant Streptococcus pneumoniae | Respiratory fluoroquinolone Beta-lactam plus macrolide |
Outpatient: macrolide-resistance streptococcus areas (>25% of infection) | Respiratory fluoroquinolone Beta-lactam plus macrolide |
Inpatient: floor | Respiratory fluoroquinolone Beta-lactam plus macrolide |
Inpatient: intensive care unit | Beta-lactam plus azithromycin or respiratory fluoroquinolone Penicillin allergic: respiratory fluoroquinolone plus aztreonam |
Inpatient: Pseudomonas | Antipseudomonal beta-lactam such as piperacillin-tazobactam, cefepime, meropenem, imipenem plus ciprofloxacin or levofloxacin |
Inpatient: methicillin-resistant Staphylococcus aureus | Vancomycin or linezolid |
- Niederman M.S.
- Bass Jr., J.B.
- Campbell G.D.
- et al.
Long-Term Host Effects
Prevention
National Center for Immunization and Respiratory Diseases. Pneumococcal Vaccine Recommendations. 2017. Available at: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html. Accessed January 22, 2018.
Summary
- •History, physical examination, including vital signs and saturation of peripheral oxygen, and chest radiographs results provide the essential information to clinically diagnose CAP.
- •CAP is caused by both bacterial and viral pathogens.
- •It is essential to query the patient’s past medical history for risk factors that predispose to drug-resistant pneumonia.
- •The concept of HCAP is changing; ED providers need to be aware of risk factors for MDR pneumonia, limiting broad spectrum antibiotics to patients satisfying guideline-recommended criteria.
- •In severe CAP, ED providers should collect blood cultures before administering antibiotics and sputum cultures when applicable, although in most cases etiologic testing does not reveal the causative pathogen.
- •Careful severity assessment is a crucial step in ED CAP management and should include screening for occult sepsis with a serum lactate, followed by early antibiotics and fluid resuscitation when indicated.
- •Risk stratification tools such as the PSI and CURB-65 should be used routinely to determine the most appropriate disposition for a patient.
- •Emergency providers should be familiar with the latest guidelines for antimicrobial treatment for both outpatient and inpatient CAP, which will continue to change as resistance patterns in respiratory pathogens evolve.
- •Vaccination must be encouraged to continue to prevent respiratory infections in children and adults.
References
- Community-acquired pneumonia.N Engl J Med. 2014; 371: 1619-1628
Rui P, Kang K. National hospital ambulatory medical care survey: 2015 emergency department summary tables. Available at: http://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2015_ed_web_tables.pdf.
- Management of community-acquired pneumonia in adults.Am J Respir Crit Care Med. 2011; 183: 157-164
- Community-acquired pneumonia requiring hospitalization among U.S. adults.N Engl J Med. 2015; 373: 415-427
- Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.Am J Respir Crit Care Med. 2005; 171: 388-416
- Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis.Clin Infect Dis. 2014; 58: 330-339
- Executive summary: management of adults with hospital-acquired and ventilator- associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Clin Infect Dis. 2016; 63: 575-582
- Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.Chest. 1999; 115: 462-474
- Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.Clin Microbiol Infect. 2006; 12: 31-41
- Antimicrobial resistance among Streptococcus pneumonaie in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?.Clin Infect Dis. 2005; 41: 139-148
- Penicillin and macrolide resistance in Pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?.Clin Infect Dis. 2004; 38: S346-S349
- Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.Intern Med. 2009; 48: 527-535
- Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.J Antimicrob Chemother. 2004; 54: i17-i22
- Macrolide-resistant mycoplasma pneumoniae, United States.Emerg Infect Dis. 2015; 21: 1470-1472
- Management of a community-acquired pneumonia: a review and update.Ther Adv Respir Dis. 2011; 5: 61-78
- Pathogenesis, treatment, and prevention of pneumococcal pneumonia.Lancet. 2009; 374: 1543-1556
- Respiratory disease.in: Colledge N.R. Walker B.R. Ralston S.H. Davidson’s principle and practice of medicine. 21st edition. Elsevier Publications, Edinburgh2010: 680-682
- Community-acquired pneumonia.N Engl J Med. 2014; 370: 543-551
- Community-acquired pneumonia.N Engl J Med. 1995; 333: 1618-1624
- Deaths: preliminary data for 2010.Natl Vital Stat Rep. 2012; 60: 1-51
- BTS guidelines for the management of community acquired pneumonia in adults.Thorax. 2009; 64: iii1-iii55
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.Pediatr Infect Dis J. 2000; 19: 187-195
- Chronic cough and a normal chest X-ray - a simple systematic approach to exclude common causes before referral to secondary care: a retrospective cohort study.NPJ Prim Care Respir Med. 2016; 26: 15081
- Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin Infect Dis. 2007; 44: S27-S72
- Community acquired pneumonia.Int J Respir Pulm Med. 2015; 2: 2
- Typical bacterial pneumonia imaging.Medscape. 2018; (Available at:)
- Imaging of community-acquired pneumonia: roles of imaging examinations, imaging diagnosis of specific pathogens and discrimination from noninfectious diseases.World J Radiol. 2014; 6: 779-793
- Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?.Arch Intern Med. 1996; 156: 2206-2212
- Interobserver reliability of the chest radiograph in community-acquired pneumonia.Chest. 1996; 110: 343-350
- Community-acquired pneumonia visualized on ct scans but not chest radiographs pathogens, severity, and clinical outcomes.Chest. 2018; 153: 601-610
- High-resolution computed tomography for the diagnosis of community-acquired pneumonia.Clin Infect Dis. 1998; 27: 358-363
- Lung ultrasound for the diagnosis of pneumonia in adults: a systematic review and meta-analysis.Respir Res. 2014; 15: 50
- Lactate on emergency department arrival as a predictor of mortality and site-of-care in pneumonia patients: a cohort study.Thorax. 2015; : 1-7https://doi.org/10.1136/thoraxjnl-2014-206461
- Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Cochrane Database Syst Rev. 2012; (CD007498)
- Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed Strategies.Crit Care Med. 2018; https://doi.org/10.1097/CCM.0000000000002953
- IDSA/ATS minor criteria aided pre-ICU resuscitation in severe community-acquired pneumonia.Eur Respir J. 2014; 43: 852-862
- A prediction rule to identify low-risk patients with community-acquired pneumonia.N Engl J Med. 1997; 336: 243-250
- Management of community-acquired pneumonia.N Engl J Med. 2002; 347: 2039-2045
- A controlled trial of a critical pathway for treatment of community- acquired pneumonia.JAMA. 2000; 283: 749-755
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.Thorax. 2003; 58: 377-382
- The Pneumonia Severity Index: a decade after the initial derivation and validation.Clin Infect Dis. 2008; 47: S133-S139
- SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia.Clin Infect Dis. 2008; 47: 375-384
- The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults.Respirology. 2006; 11: S79-S133
- An appraisal of the evidence underlying performance measures for community-acquired pneumonia.Am J Respir Crit Care Med. 2011; 183: 1454-1462
- Risk Factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia.Acad Emerg Med. 2012; 19: 703-706
- Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia: results of a prospective observational study.Clin Microbiol Infect. 2013; 19: E142-E148
- Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.Am J Med. 2007; 120: 783-790
- Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clin Infect Dis. 2011; 52: e18-e55
- Guidelines for the initial management of adults with community- acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.Am Rev Respir Dis. 1993; 148: 1418-1426
- Corticosteroid therapy for patients hospitalized with community-acquired pneumonia. A systematic review and meta-analysis.Ann Intern Med. 2015; 163: 519-528
- Corticosteroids for community-acquired pneumonia: a critical view of the evidence.Eur Respir J. 2016; 48: 984-986
- Effects of hospital-based physical therapy on hospital discharge outcomes among hospitalized older adults with community-acquired pneumonia and declining physical function.Aging Dis. 2015; 6: 174-179
- The efficacy of penicillin V (phenoxymethyl- penicillin) in the treatment of mild and of moderately severe pneumococcal pneumonia.Am J Med Sci. 1956; 232: 624-628
- Measuring symptomatic and functional recovery in patients with community-acquired pneumonia.J Gen Intern Med. 1997; 12: 423-430
- Pneumonia: still the old man’s friend?.Arch Intern Med. 2003; 163: 317-323
- Is pneumonia really the old man’s friend? Two-year prognosis after community-acquired pneumonia.Lancet. 1993; 342: 30-33
- Medium-term survival after hospitalization with community-acquired pneumonia.Am J Respir Crit Care Med. 2004; 169: 910-914
- Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study.Arch Intern Med. 1999; 159: 1550-1555
- Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.Stroke. 2006; 37: 1923-1932
- Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events.Am J Cardiol. 2015; 116: 647-651
- Determining best outcomes from community-acquired pneumonia and how to achieve them.Respirology. 2018; 23: 138-147
National Center for Immunization and Respiratory Diseases. Pneumococcal Vaccine Recommendations. 2017. Available at: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html. Accessed January 22, 2018.
- Vaccines for preventing pneumonia in chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2017; (CD001390)
Article info
Publication history
Footnotes
Disclosure Statement: The authors have nothing to disclose.